Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Trial Profile

Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Darinaparsin (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Solasia Pharma
  • Most Recent Events

    • 28 Mar 2016 Based on the results of this trial, Solasia intends to file for registration in Japan, South Korea, Taiwan and Hong Kong according to a company media release.
    • 01 Mar 2016 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018 as reported by ClinicalTrials.gov.
    • 01 Mar 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top